Denovicon Therapeutics is a company based in San Diego developing small-molecule therapeutics using software including proprietary AI–molecular modeling algorithm. They utilize:
- decades of drug discovery experience,
- a proven computational platform,
- state-of-the-art hardware infrastructure,
- and a proprietary AI–molecular modeling (hybrid) algorithm
to accelerate the development of small-molecule therapeutics. Denovicon Therapeutics aim to reduce the preclinical development timeline of pharmaceutical drug discovery projects from 6 years to 2-3 years.
Founded in 2019 their initial focus is small-molecule therapies for oncology and immuno-oncology targets. The founder and CEO of Denovicon Therapeutics is Scott Bembenek, former computer-aided drug discovery principal scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson.
In January 2020 the company announced a partnership with Scientist.com, an AI-powered pharmaceutical company. The partnership will see the companies combine their proprietary AI procurement and AI molecular modeling platforms to speed up medical research.